The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies
February 19th 2024Matthew Pianko, MD, outlines the logistical considerations involved when implementing bispecific antibodies for the treatment of multiple myeloma, including the roles of the project champion and other stakeholders as part of a multidisciplinary team.
Balancing Opioid Management Challenges for Health Care Professionals
February 15th 2024Experts explore using technology and data analytics to enhance opioid stewardship programs, addressing challenges health care professionals face, and providing strategies for effective patient care, leveraging data, and fostering supportive environments.
Expert Discusses Quality Standards' Role in the Evolution of Biosimilars and Biologics Landscape
February 13th 2024Fouad Atouf, senior vice president of global biologics at US Pharmacopeia, discusses how established quality standards, drawing from the realm of small molecule drugs and evolving to meet the complexities of biologics, play a pivotal role in fostering trust.
Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies
February 12th 2024Anthony Perissinotti, PharmD, BCOP, provides an overview of the REMS program requirements for bispecific antibodies and describes the processes, procedures, and training programs implemented at his institution.
Implementing Bispecific Antibodies in Lymphoma Care
February 9th 2024Experts provide practical guidelines and key takeaways for health care professionals and policymakers on the implementation of bispecific antibodies in DLBCL (diffuse large B cell lymphoma), emphasizing safety, efficacy, and operational strategies.
Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody
February 7th 2024Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.